Original Source(s)
Related Content
ESMO26: Toni Choueiri, MD, on KEYNOTE-564
Final analysis of the pivotal KEYNOTE-564 trial in kidney cancer presented by Toni Choueiri, MD. After 7 years of follow-up, adjuvant pembrolizumab continued to extend disease-free survival and overall survival in high-risk clear-cell renal cell carcinoma.
November 17, 2026
-
1 min
FDA Investigates Malignancy Risk Linked to Zolgensma Gene Therapy
Vector DNA integration was identified near or within the GLI1 oncogene in tumors from two treated patients
November 16, 2026
-
3 min
ESMO26: Vincent Xu, MD on KIM1 in Kidney Cancer
Vincent (Wenxin) Xu, MD , shows among patients with advanced kidney cancer on immunotherapy alone, KIM-1 reductions were seen in immune-inflamed tumors, while no KIM-1 drop was linked to immune-depleted tumors.
November 17, 2026
-
1 min